The temporary inhibition of the enzyme ATGL prevents insulin resistance and the development of non-alcoholic fatty liver disease. In the picture: liver- and fat cells in detail.
Scientists at the University of Graz and TU Graz have developed an active ingredient that reduces obesity and can prevent type II diabetes as well as non-alcoholic fatty liver disease. According to the World Health Organisation (WHO), around 1.9 billion people are overweight worldwide. 75 per cent suffer from non-alcoholic fatty liver disease and 400 million have type II diabetes. In addition to the psychosocial consequences of obesity, related diseases lead to a decrease in quality and length of life. Scientists at the University of Graz and Graz University of Technology have now developed an active ingredient that reduces obesity and can prevent type II diabetes as well as non-alcoholic fatty liver disease. The research results of the working groups of Rudolf Zechner, Robert Zimmermann (both University of Graz) and Rolf Breinbauer from Graz University of Technology were published in renowned scientific . Insulin resistance as precursor of type II diabetes.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
